Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75

BACKGROUND: CD70 is an ideal target for antibody-based therapies because of its aberrant high expression in renal carcinomas and non-Hodgkin lymphomas and its highly restricted expression in normal tissues. The expression profiling of CD70 in carcinomas has been limited because of the lack of a CD70...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ryan, M C, Kostner, H, Gordon, K A, Duniho, S, Sutherland, M K, Yu, C, Kim, K M, Nesterova, A, Anderson, M, McEarchern, J A, Law, C-L, Smith, L M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2010
Assuntos:
Molecular Diagnostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2938259/
https://ncbi.nlm.nih.gov/pubmed/20664585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605816
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados